Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 18 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant TherapyNot yet recruitingNCT04973319Phase 3
- Baricitinib in Patients With Relapsing or naïve DermatomyositisRecruitingNCT04972760Phase 3
- Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)Not yet recruitingNCT04965831Phase 2
- NCCH2006/MK010 Trial (FORTUNE Trial)RecruitingNCT04962867Phase 2
- Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System LymphomaRecruitingNCT04961515Phase 2
- A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerNot yet recruitingNCT04958473Phase 2
- A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingNCT04951635Phase 3
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingNCT04941716Phase 2
- Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaRecruitingNCT04938297Phase 2
- Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR MutationRecruitingNCT04936295Phase 2
- Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal TumorsRecruitingNCT04933669Phase 2
- Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HPNot yet recruitingNCT04929548Phase 4
- Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsRecruitingNCT04925609Phase 1/2
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaRecruitingNCT04925479Phase 1/2
- Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade PatternsRecruitingNCT04922138Phase 2
- A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast CancerRecruitingNCT04914390Phase 2
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisRecruitingNCT04910685Phase 2/3
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid TumorRecruitingNCT04906434Phase 1
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingNCT04903119Phase 1
- Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingNCT04900311Phase 2
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)RecruitingNCT04893785Phase 2
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruitingNCT04886531Phase 2
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingNCT04883437Phase 2
- Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid TumorsRecruitingNCT04879121Phase 2
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingNCT04878003Phase 2
- Asciminib Roll-over StudyRecruitingNCT04877522Phase 4
- Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCRecruitingNCT04875585Phase 2
- Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALRecruitingNCT04872478Phase 1
- Study of Salvage Therapy to Treat Patients With Granulomatosis With PolyangiitisRecruitingNCT04871191Phase 3
- Pembrolizumab and Lenvatinib in Advanced Cervical CancerRecruitingNCT04865887Phase 2
- Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingNCT04858516Phase 2
- Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsRecruitingNCT04858256Phase 2
- Avo In R/R And Previously Untreated MCLRecruitingNCT04855695Phase 1/2
- To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingNCT04853342Phase 3
- Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingNCT04838041Phase 2
- Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLRecruitingNCT04835870Phase 2
- Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBIRecruitingNCT04829019Phase 2
- A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR MutationsRecruitingNCT04816838Not applicable
- Phase Ib Clinical Study of KeynatinibRecruitingNCT04807881Phase 1
- A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBCRecruitingNCT04803539Phase 2/3
- A Phase I Study of WM-S1-030 in Patients With Advanced Solid TumorsRecruitingNCT04801095Phase 1
- Safety and Efficacy of Itacitinib in Adults With Systemic SclerosisRecruitingNCT04789850Phase 2
- Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric CancerRecruitingNCT04781686Phase 2
- Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerRecruitingNCT04780568Phase 1
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.RecruitingNCT04775745Phase 1
- Phase I Study of Repotrectinib and Osimertinib in NSCLC PatientsRecruitingNCT04772235Phase 1
- A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT04772079Phase 3
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsRecruitingNCT04771520Phase 2
- A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04771507Phase 1/2
- Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Phase 3
- MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerRecruitingNCT04762199Phase 1
- Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04758975Phase 2
- Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung CancerNot yet recruitingNCT04755738Phase 2
- A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With ChemoradiotherapyRecruitingNCT04749394Phase 2
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingNCT04747912Phase 2
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 2
- A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-MutatedRecruitingNCT04716114Phase 3
- Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid LeukemiaNot yet recruitingNCT04709731Phase 2
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingNCT04693468Phase 1
- Study in Adult Ph-positive ALLNot yet recruitingNCT04688983Phase 2
- A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid TumorsRecruitingNCT04685226Phase 1/2
- Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene AbnormalitiesRecruitingNCT04683250Phase 1/2
- Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT04659616Phase 1
- A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK FusionRecruitingNCT04655404Early Phase 1
- Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisRecruitingNCT04655118Phase 2
- Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRCRecruitingNCT04653480Phase 2
- Merck IIT: RRP Pembro and LenvatinibRecruitingNCT04645602Phase 2
- Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersRecruitingNCT04645160Phase 1/2
- Ruxolitinib in Thrombocythemia and Polycythemia VeraRecruitingNCT04644211Phase 2
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaRecruitingNCT04625907Phase 1/2
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingNCT04610476Phase 3
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaRecruitingNCT04598009Phase 2
- Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)RecruitingNCT04591002Phase 2
- Study to Evaluate the Safety and Tolerability of EP0042RecruitingNCT04581512Phase 1/2
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3
- Imatinib Mesylate in Combination With Pembrolizumab in Patients With MelanomaRecruitingNCT04546074Phase 1/2
- Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary FibrosisRecruitingNCT04541680Phase 3
- Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerRecruitingNCT04519151Phase 2
- Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in AdultsRecruitingNCT04501705Not applicable
- An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial CancerRecruitingNCT04492293Phase 2
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingNCT04486833Phase 1/2
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2
- A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid LeukemiaRecruitingNCT04471064Phase 1
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingNCT04455594Phase 2
- Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II StudyRecruitingNCT04454905Phase 2
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelRecruitingNCT04449549Phase 2
- Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )RecruitingNCT04443322Not applicable
- Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous LineageRecruitingNCT04440267Phase 2
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
- Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerRecruitingNCT04415853Phase 3
- Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersRecruitingNCT04410796Phase 2
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingNCT04404088Phase 2
- A Study of KC1036 in Patients with Advanced Solid TumorsRecruitingNCT04387916Phase 1
- Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 2
- HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04353375Phase 2/3
- Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCRecruitingNCT04342910Phase 3
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2